Akebia Therapeutics Q4 2025 Earnings Call Highlights: Revenue, Guidance, and Pipeline Updates

Akebia Therapeutics reported Q4 2025 financial results, with CEO John Butler and CFO Erik Ostrowski discussing the company's performance. Key points included a 12% YoY increase in Vafseo net product revenue to $76.8 million and a $25 million milestone payment from AstraZeneca for the EU approval of Vafseo. The company's full-year revenue for Vafseo was $287.8 million, exceeding its full-year 2025 guidance of $270 million.